Health Care · Pharmaceutical Preparations · NYSE · CIK 728387 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $2.99Day +4.18%Mkt cap $327M1Y −22.9%Off 52W high −51.5%Vol (1Y) 110.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 842 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest20.0% of sh out |
| Days to cover10.0d |
| 13F net flow (QoQ)+22.63% |
| Top-10 13F concentration63.6% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$8.8M |
| Earnings (TTM)-$111.1M |
| ROE−41.4% |
| ROIC−138.7% |
| Debt / equity0.01× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+8.7% |
| 1Y−22.9% |
| 3Y−47.5% |
| Since incept. (ann.)−13.3% |
Total return through 2026-07-30 · series begins 2023-03-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)110.6% |
| Ann. volatility (3Y)112.7% |
| Sharpe (1Y)0.24 |
| Sharpe (3Y)0.36 |
| Max drawdown (1Y)−58.8% |
| Max drawdown (3Y)−90.7% |
| Beta (3Y vs SPY)0.93 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Avidity Partners Management LP | 12.1M | $49M | 10.62% | +276.9% |
| TCG Crossover Management, LLC | 7.9M | $33M | 6.95% | new |
| Commodore Capital LP | 6.3M | $26M | 5.56% | new |
| BlackRock, Inc. | 5.3M | $22M | 4.69% | +17.3% |
| Opaleye Management Inc. | 4.7M | $19M | 4.10% | +294.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $18M | 3.84% | new |
| MILLENNIUM MANAGEMENT LLC | 4.0M | $17M | 3.55% | +187.7% |
| CITADEL ADVISORS LLC | 3.6M | $15M | 3.13% | +1218.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.25 | — | — | — |
| 2025-09-30 | 2025-11-10 | −$0.35 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.29 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.25 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
